Seattle startup Oisín Biotechnologies raises $15M to develop therapies for age-related diseases
GeekWire
JULY 24, 2024
The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty. Scholz is also CEO of OncoSenX , which spun out of Oisín in 2018 and is studying the treatment of solid tumors.
Let's personalize your content